Table 2.
Analysis of costs of each screening strategy
| Cost Measures | TST | T-SPOT.TB | QFT-GIT | TST/T-SPOT.TB | TST/QFT-GIT | No screening |
|---|---|---|---|---|---|---|
| Treatment & follow-up costs | £184,156 | £148,983 | £157,921 | £127,402 | £125,618 | £57,148 |
| Test costs | £15,433 | £55,000 | £45,000 | £34,986 | £31,431 | £0 |
| Total costs | £199,589 | £203,983 | £202,921 | £162,387 | £157,048 | £57,148 |
| Breakdown of costs associated with test inaccuracies | ||||||
| Costs incurred on false positives | £55,090 | £0 | £16,313 | £0 | £3,038 | - |
| Costs incurred on false negatives | £8,369 | £3,682 | £7,771 | £11,371 | £14,721 | - |
| Costs incurred on TST non-returns | £6,622 | £0 | £0 | £6,622 | £6,622 | - |
All costs are expressed in British pounds (£). Costs relate to outcomes and costs for entire cohort of 1,000 contacts over the 2 year examination period. (TST - Tuberculin Skin Test, QFT-GIT - Quantiferon-TB Gold-In-Tube)